Nektar Therapeutics - NKTR STOCK NEWS

Nektar Therapeutics (NKTR) has announced its upcoming participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025. The company will host a fireside chat at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time).

The presentation will be accessible through a webcast link and the Investor Events section of Nektar's website. Interested parties can access the replay for 30 days following the event. One-on-one meetings with management can be arranged through H.C. Wainwright representatives.

Nektar Therapeutics (NKTR) reported Q4 and full year 2024 financial results. The company ended 2024 with $269.1 million in cash and investments, down from $329.4 million in 2023. Q4 2024 revenue increased to $29.2 million from $23.9 million year-over-year, while full-year revenue rose to $98.4 million from $90.1 million.

The company reported Q4 2024 net income of $7.3 million ($0.03 per share), compared to a net loss of $42.1 million in Q4 2023. Full-year 2024 net loss was $119.0 million ($0.58 per share), improved from $276.1 million in 2023. Operating expenses decreased significantly to $203.6 million in 2024 from $353.8 million in 2023, partly due to a $40.4 million gain from the Huntsville facility sale.

Key developments include completed enrollment in Phase 2b trials for rezpegaldesleukin in atopic dermatitis and alopecia areata, with topline data expected in Q2 and Q4 2025. The company also sold its Huntsville manufacturing business to Ampersand Capital Partners for $90 million in enterprise value.

Nektar Therapeutics (NKTR) has scheduled its fourth quarter and full-year 2024 financial results announcement for Wednesday, March 12, 2025, after U.S. market close. The company will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, led by President and CEO Howard Robin, to discuss the results.

The earnings call will be accessible through an audio-only webcast available on Nektar's investor relations website. The webcast recording will remain available for replay until April 12, 2025. Interested participants must pre-register through the Nektar Earnings Call Registration system to receive dial-in information and a PIN for call access.

Nektar Therapeutics (NKTR) has completed target enrollment of 84 patients in its REZOLVE-AA Phase 2b clinical trial studying rezpegaldesleukin for severe-to-very severe alopecia areata. The study, initiated in March 2024, spans approximately 30 sites globally with enrollment distribution of 62% in Poland, 24% in Canada, and 14% in the United States.

Rezpegaldesleukin is an investigational biologic therapy targeting the interleukin-2 receptor complex to stimulate regulatory T cells (Tregs) proliferation. The trial includes patients with ≥50% scalp involvement who haven't received JAK inhibitors or other biologics, randomized across two dose regimens or placebo.

The primary endpoint will assess mean percent change in Severity of Alopecia Tool (SALT) score at 36 weeks. Secondary endpoints include the proportion of participants achieving ≥50% SALT score reduction and SALT-20. Topline data is expected in Q4 2025.

Nektar Therapeutics (NKTR) and TrialNet announced a collaboration to evaluate rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D). The Phase 2 randomized, double-blind, placebo-controlled trial will involve approximately 70 adults and children with new onset stage 3 T1D.

Rezpegaldesleukin is a novel T regulatory (Treg) cell biologic designed to reduce inflammation and restore immune balance. Under the agreement, TrialNet will conduct the trial while Nektar provides the drug and analytical support. The study, planned to initiate in 2025, will measure efficacy using a mixed meal tolerance test to assess C-peptide levels over 12 months, including a 6-month treatment period and 6-month follow-up. Secondary objectives include pharmacokinetics, pharmacodynamics, HbA1c levels, and insulin requirements.

Nektar Therapeutics (NKTR) has announced a virtual investor and analyst event focusing on Type 1 Diabetes (T1D) scheduled for February 24, 2025, at 3:00 p.m. EST / 12:00 p.m. PST. The event will be hosted by Jonathan Zalevsky, Ph.D., Nektar's Chief Research & Development Officer.

The webcast will feature prominent diabetes experts including Dr. Kevin Herold from Yale School of Medicine, Dr. Megan Levings from The University of British Columbia, and Dr. Daniel Moore from Vanderbilt University Medical Center. Participants must pre-register for the conference call through Event Registration.

The event recording will remain accessible for replay on Nektar's website until March 24, 2025.

Nektar Therapeutics (NKTR) has received FDA Fast Track designation for rezpegaldesleukin, a treatment for moderate-to-severe atopic dermatitis in patients 12 years and older whose condition isn't adequately controlled by topical prescriptions. The investigational biologic therapy targets the interleukin-2 receptor complex to stimulate regulatory T cells.

Clinical data has shown rapid improvement in disease outcomes during a 12-week induction treatment phase, with benefits lasting at least 36 weeks post-treatment. The company expects to announce topline data from their Phase 2b REZOLVE-AD study in Q2 2025.

The Fast Track designation enables more frequent FDA interactions and potential eligibility for rolling review and priority review, aimed at accelerating the development process for treatments addressing serious conditions with unmet medical needs.

Nektar Therapeutics (NKTR) has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin for moderate-to-severe atopic dermatitis. The 396-patient trial, initiated in October 2023, reached full enrollment in just 14 months across approximately 110 global sites.

The study focuses on patients who haven't previously received biologic or JAK inhibitor therapies. Participants are randomized across three dose regimens or placebo for a 16-week induction treatment period. The primary endpoint measures improvement in EASI score, with secondary endpoints including vIGA-AD, EASI-75, and Itch NRS improvements.

Geographic distribution of enrollment includes: 67% in European countries, 17% in the United States, 11% in Canada, and 5% in Australia. Previous clinical trials demonstrated that rezpegaldesleukin safely increased Tregs and improved disease outcomes, with effects lasting up to 36 weeks post-treatment.

Nektar Therapeutics (NKTR) announced positive results from its Phase 2 study of NKTR-255 as an adjuvant treatment following CD19-directed CAR-T therapy in patients with relapsed/refractory Large B-cell Lymphoma. The study showed that 73% of patients in the NKTR-255 treatment group achieved complete response at 6 months compared to 50% in the placebo group.

The multicenter, double-blind trial demonstrated that NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve being 5.8-fold greater than placebo-controls. Two patients treated with NKTR-255 converted from stable disease or partial response to complete responses at six months, while no conversions were observed in the placebo arm.

The treatment was reported to be safe and well-tolerated, with results surpassing historical benchmark data showing 41% to 44% complete response rates at 6 months.